Deals & Filings
Page 1 of 4 · 57 articles on this desk
All Deals & Filings coverage
27 Startups. One Ticker. How Scalare Partners (ASX: SCP) Turned a Founder Pipeline Into a Listed Portfolio
Scalare sees Australia's best early-stage founders before anyone else does. Then it invests. Then it lodges the numbers. Read them before the crowd.
Eastern International Draws a $1 Bid-Price Notice, Opening a First 180-Day Clock to March 9, 2027
The Hangzhou logistics and infrastructure-construction issuer disclosed a Nasdaq deficiency letter under Rule 5550(a)(2) on Friday. Its shares last changed hands around two-thirds of the level it needs to hold for ten straight sessions, and the March 2027 date is the first deadline, not the last.
NextNRG's 1-for-10 reverse split takes effect on the last day of its Nasdaq bid-price compliance period
The company said Thursday the split becomes effective at 12:00 a.m. ET on Monday, Sept. 14 — the date its Form 8-K gives as the end of the 180-day period to regain compliance with Nasdaq's $1.00 minimum bid price rule. Nasdaq's rules require at least ten consecutive business days at the standard to cure, and only one split-adjusted session falls inside the window. NextNRG held $883,696 of cash at June 30 against a $6,624,702 GAAP quarterly loss, with two secured loans maturing Oct. 1.
NeOnc Technologies prices $15 million registered direct at $4.20 with one-for-one warrant coverage
The Nasdaq-listed brain-cancer developer is selling about 3.57 million shares or pre-funded warrants, each unit carrying a five-year warrant at the same $4.20 exercise price. The company reported roughly $2.0 million of cash at June 30 and a $14.2 million second-quarter net loss.
Xiao-I's 1-for-7 ADS Ratio Change Takes Effect Today, Leaving the Ordinary Share Count Untouched
Each American depositary share now represents 420 ordinary shares instead of 60. The company's open Nasdaq deficiency is a $15 million market-value test rather than the $1 bid price, and it runs to Feb. 1, 2027.
Matinas BioPharma Falls Below the Last of NYSE American's Three Stockholders' Equity Standards
An Aug. 31 notice, disclosed Friday, adds Section 1003(a)(i) to two the company was already breaching. Equity was $1.8 million at June 30 against a $2.0 million floor, and the exchange's plan period runs to Oct. 2, 2027.
La Rosa Holdings Sets a 1-for-6 Reverse Split for Tuesday, the Fourth Consolidation It Has Announced Since July 2025
The Nasdaq-listed real estate brokerage says it has not received a bid-price deficiency notice and is acting before one arrives, the same framing it used in January and April. Share counts published in each of the four announcements show the float rebuilding between every split.
Polyrizon Prices a $4.0 Million Registered Direct and Concurrent Private Placement at $12.00 a Unit, With One Warrant Attached to Every Unit
The Nasdaq-listed nano-cap said the deal covers 333,333 units and 333,333 private placement common warrants struck at the same $12.00. It expects to close today; the company said last year, after a Nasdaq hearings panel process, that it would avoid what its chief executive called overly complex or inherently dilutive financing instruments.
Tantech Sets 1-for-50 Reverse Split for Sept. 4, Its Second Share Consolidation in 19 Months
The Nasdaq-listed company's record date falls today, weeks ahead of the compliance deadline reported for a bid-price deficiency it received in March. Combined with a 1-for-40 split in February 2025, the two consolidations total 2,000-to-1 in about 19 months.
Cyabra Holders Approve Retiring All Three Preferred Series, Removing Conversion-Price Resets and Leaving a 123% Resale Registration
The AI narrative-intelligence company said stockholders backed the conversion and exchange with about 98% of votes cast. The transactions have not closed, and a resale registration filed Sept. 1 covers more shares than are currently outstanding.
Intelligent Bio Solutions Prices Private Placement Expected to Bring About $5.0m at Closing; the Balance Rests on Two Warrant Series, Neither Yet Exercisable in Full
The Nasdaq-listed drug-screening company said on Sept. 1 it had agreed a private placement expected to produce approximately $5.0m of gross proceeds at closing, which it said was expected on or about Sept. 2. The release's up-to-$15m headline is reached only if two warrant series are exercised in full for cash: one the company can force only after it publicly announces FDA 510(k) clearance, the other not exercisable at all until shareholders approve.
Shengfeng Development Sets 1-for-15 Reverse Split for Sept. 8; the Release Gives No Reason for It
The Fuzhou-based contract logistics company will consolidate both share classes 15-to-1, with its Class A ordinary shares to begin trading on a split-adjusted basis at the market open on Monday, taking roughly 82.5m ordinary shares down to about 5.5m. Its announcement states no purpose for the split and makes no reference to any Nasdaq listing rule, bid-price requirement or deficiency.
ENvue Medical's Third Reverse Split Since 2025 Takes Effect Under a Nasdaq Delisting Determination
The enteral-care device maker's 1-for-12 consolidation became effective Tuesday, cutting shares outstanding from 11.08 million to roughly 923,700. Proxy materials disclose that ENvue was ruled ineligible for any Nasdaq bid-price compliance period because it had effected a reverse split within the prior one-year period, and its most recent quarterly report carries substantial-doubt going-concern language.
Capstone Holding Maps Remaining Convertible-Note Dilution and an Unused Reverse-Split Window
An August 26 filing from the building-products roll-up puts potential dilution from its remaining convertible notes at about 28 percent of shares outstanding, after the conversion price was cut to $0.2949 earlier in the month. The company trades below Nasdaq's $1.00 minimum with a compliance period running to January 4, 2027 and shareholder authority for a reverse split it has not yet used.
Glucotrack's 1-for-15 reverse split takes effect; its latest quarterly report shows $1.12m of cash and going-concern doubt
The share consolidation that took effect at Monday's open shrinks Glucotrack's common count to roughly 798,000 shares. The company's most recent quarterly report, covering the period ended June 30, 2026, carries substantial-doubt going-concern language and $1.12m of cash. Separately, a business combination completed in July would leave former Lōkahi Therapeutics securityholders with about 90 percent of the company on a fully diluted basis once preferred stock converts — a step the company says still requires stockholder approvals and Nasdaq clearance.
MicroVision clears its Nasdaq bid-price deficiency seven months on, after a 1-for-15 split and a $17m raise at $2.50
MicroVision said Monday that Nasdaq confirmed on August 26 that the company had regained compliance with the exchange's $1 minimum bid price rule and closed the matter. The cure followed a reverse split effective August 1 and a registered offering priced two weeks later that added 6.8m shares and an equal number of five-year warrants.
Cycurion's 1-for-8 Reverse Split Takes Effect Friday While Its Nasdaq Delisting Appeal Is Still Live
The consolidation cuts shares outstanding from about 25.8 million to about 3.2 million and is aimed at the exchange's minimum bid price rule. A separate Nasdaq standard the SEC approved in July measures market value, which a reverse split does not change.
Greenland Mines Prices $20 Million Offering of 4 Million Shares Two Days After 1-for-50 Reverse Split
The 4 million shares being sold exceed the roughly 3.18 million shares the company said were outstanding after Monday's split. A separate Aug. 24 filing set up an at-the-market facility of up to $50 million on top of the offering.